Printer Friendly

Genesis CancerCare Queensland uses the Venezia Brachytherapy Applicator in patients with advanced cervical cancer for the first time.

M2 PHARMA-September 11, 2017-Genesis CancerCare Queensland uses the Venezia Brachytherapy Applicator in patients with advanced cervical cancer for the first time

(C)2017 M2 COMMUNICATIONS

Elekta announced on Friday that the clinicians at Genesis CancerCare Queensland delivered the first of three high dose rate brachytherapy treatments to a woman with loco-regionally advanced stage (IIB) cervical cancer via its Venezia applicator.

Following the patient's post-chemoradiation brachytherapy boost treatments, Elekta is reportedly the first company in the Australia / Asia-Pacific region to use the Venezia Advanced Gynecological Applicator.

The company said Venezia is designed to treat not only the cervix using an intracavitary technique, but also disease extensions in the parametrium and vagina employing interstitial needles. The applicator enables doctors to treat advanced stages of cervical cancer, including IIIA and IIIB with vaginal and parametrial extensions.

According to the company, the "clickable" design of Venezia contributes in large part to making insertion in the patient simple.

Genesis CancerCare is Australia's leading provider of radiotherapy treatments, performing 360,000 treatments across its national network each year.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Geographic Code:8AUST
Date:Sep 11, 2017
Words:183
Previous Article:Zavante Therapeutics signs clinical trial contract with National Institute of Allergy and Infectious Disease.
Next Article:PharmScript reports acquisition of MedCart Pharmacy for undisclosed value.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters